saquinavir sold brand name invirase among others antiretroviral medication used together medications treat prevent typically used ritonavir lopinavirritonavir increase taken common side effects include nausea vomiting diarrhea feeling serious side effects include problems qt prolongation heart block high blood lipids liver appears safe protease inhibitor class works blocking hiv saquinavir patented first sold saquinavir used together medications treat prevent typically used ritonavir lopinavirritonavir increase frequent adverse events saquinavir either formulation mild gastrointestinal symptoms including diarrhoea nausea loose stools abdominal discomfort invirase better tolerated fortovasemedical citation needed saquinavir invirase formulation low variable oral bioavailability given alone fortovase formulation standard dosage delivers approximately eightfold active drug invirase also standard clinic found oral bioavailability saquinavir formulations significantly increases patients also receive pi ritonavir patients major benefit take less saquinavir maintaining sufficient saquinavir blood plasma levels efficiently suppress replication hivmedical citation needed mechanism behind welcome observation directly known later determined ritonavir inhibits cytochrome isozyme normally enzyme metabolizes saquinavir inactive form ritonavir inhibiting enzyme saquinavir blood plasma levels increased considerably additionally ritonavir also inhibits multidrug transporters although much lower extentmedical citation needed unlike protease inhibitors absorption saquinavir seems improved saquinavir protease inhibitor proteases enzymes cleave protein molecules smaller fragments hiv protease vital viral replication within cell release mature viral particles infected cell saquinavir binds active site viral protease prevents cleavage viral polyproteins preventing maturation virus saquinavir inhibits saquinavir developed pharmaceutical company saquinavir sixth antiretroviral first protease inhibitor approved us food drug administration fda leading ritonavir indinavir new class antiretrovirals played critical role development highly active antiretroviral therapy haart helped significantly lower risk death aidsrelated causes seen reduction annual us hivassociated death rate period two roche requested received approval invirase via fdas accelerated approval process designed speed drugs market treatment serious decision controversial aids activists disagreed benefits thorough testing versus early access new source needed approved november soft gel capsule reformulated improved bioavailability roche announced may given reduced demand fortovase would cease marketed early favor invirase boosted owing ability latter coformulated drug inhibit enzyme metabolizes aids drugscitation needed available generic two formulations marketed httpsenwikipediaorgwikisaquinavir